Table 2.

Summary of cohorts and dose escalation based on dose-limiting toxicity

	Part	Selumetinib dose	n (evaluable for dose escalation)	Evaluable patients with a DLT	DLT information
Selumetinib in combination with docetaxel
	A	50 mg BID	7 (6)	0	NA
		75 mg BID with ppG-CSF	7 (6)	0	NA
		75 mg BID without ppG-CSF	8 (5)	2	Grade 4 neutropenia with fever (n = 1) Grade 4 thrombocytopenia (n = 1)
	B	75 mg BID with ppG-CSF	12 (NA)	NA	NA
		75 mg BID without ppG-CSF	1 (NA)	NA	NA
Selumetinib in combination with dacarbazine
	A	50 mg BID	7 (6)	1	Grade 4 thrombocytopenia (n = 1)
		75 mg BID	6 (6)	0	NA
	B	75 mg BID	12 (NA)	NA	NA

BID, twice daily; DLT, dose-limiting toxicity; NA, not applicable; ppG-CSF, primary prophylactic granulocyte-colony stimulating factor